MARKET

MDCX

MDCX

Medicus Pharma Ltd
NASDAQ
2.050
+0.130
+6.77%
After Hours: 2.099 +0.049 +2.39% 19:41 12/05 EST
OPEN
2.010
PREV CLOSE
1.920
HIGH
2.100
LOW
1.930
VOLUME
370.91K
TURNOVER
--
52 WEEK HIGH
8.94
52 WEEK LOW
1.675
MARKET CAP
45.16M
P/E (TTM)
-1.0391
1D
5D
1M
3M
1Y
5Y
1D
Medicus Pharma Raises $5.1 Million Through Warrant Exercise
Reuters · 11h ago
Medicus Pharma Ltd. Strengthens Leadership and Expands Clinical Trials
TipRanks · 4d ago
Medicus Pharma appoints new CFO
Seeking Alpha · 4d ago
Medicus Pharma appoints Carolyn Bonner as CFO
TipRanks · 4d ago
Medicus Pharma Names Carolyn Bonner President and CFO
Reuters · 4d ago
MEDICUS PHARMA LTD. APPOINTS CAROLYN BONNER AS CHIEF FINANCIAL OFFICER IN ADDITION TO HER ROLE AS PRESIDENT
Reuters · 4d ago
Weekly Report: what happened at MDCX last week (1124-1128)?
Weekly Report · 4d ago
Medicus Pharma explores novel treatment innovations for prostate, skin cancers
TipRanks · 11/24 13:15
More
About MDCX
Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. SkinJect Inc., a wholly owned subsidiary of the Company, is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver a chemotherapeutic agent to eradicate tumors cells. It is conducting a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-003) in the United States and Europe. It has also commenced a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-004) in the UAE. Its subsidiary, Antev Limited, is a late clinical stage biotech company, developing Teverelix, a GnRH antagonist, as a first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse episodes due to enlarged prostate.

Webull offers Medicus Pharma Ltd stock information, including NASDAQ: MDCX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MDCX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MDCX stock methods without spending real money on the virtual paper trading platform.